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Abstract: Animal models of stroke provide an essential tool for the understanding of the complex cellular and molecular 
pathophysiology of stroke and for testing novel recanalyzing, neuroprotective, neuroregenerative or anti- inflammatory 
drugs in pre- clinical setting. Since the first description of the distal occlusion of the middle cerebral artery (MCA) in rats, 
different techniques and methods to induce focal and global ischemia of the brains have been developed and optimized. 
The different models, ranging from proximal to distal MCA occlusion to embolic and photothrombotic stroke vary widely 
in their ability to model human disease and in their application to the study of cell death, inflammation and neural repair. 
In the first part of the review animal models developed for studying stroke related risk factors are described while this sec-
tion discusses specific models that have been created for mimicking different types of stroke, focal and global ischemia in 
an experimental setup. Advantages and limits and the potential of the diverse models for the study of novel therapies as 
well as for the study of basic pathophysiological mechanisms are explored.  
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INTRODUCTION 
  From the late 1970s, animal models of cerebral ischemia 
were developed with the aim of identifying mechanisms that 
cause tissue damage and to provide the basis for the devel-
opment, at a preclinical level, of new therapies for stroke. 
Several recent animal models have been designed specifi-
cally to address specific risk factors, to determine neural 
repair processes, to test new neuroprotective and recanaliz-
ing strategies. Today reliable animal models for stroke are 
available in a variety of species including primates, pigs, 
sheep, dogs, cats, mongolian gerbils, rabbits, rats and mice.  
  Although the use and development of primate and higher 
mammal stroke models is a very important goal, small ani-
mals are actually privileged at a preclinical level for the fol-
lowing reasons: they are well-suited for ischemic strokes, 
physiological variables can reasonably be monitored and 
sufficient numbers for statistical analysis can be reached 
without excessive costs [1]. In stroke studies the rat is the 
most commonly used animal because of its size that allows 
easy monitoring of the physiologic variables and handling of 
vascular structures.  
  Nonetheless since the mouse is the best-characterized 
animal in genetics and molecular biology, many transgenic 
animals being available in this species, an increasing number 
of stroke studies were carried out in mice from the 1990s 
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Stroke models can be divided into two main categories:  
1.  Models to study how risk factors (both environmental 
and genetic) may contribute to vascular damage that 
ultimately leads to stroke (i.e. models of atherosclero-
sis, hypercholesterolemia, hyper-homocysteinemia, 
arterial hypertension and single-gene disorders asso-
ciated with stroke such as CADASIL) and therapeuti-
cal approaches to prevent stroke events- (These mod-
els are discussed in the first part of the review: “Part 
one: Modeling risk factors”). 
2.  Models for the study of the pathophysiological con-
sequences of stroke, and for testing therapeutical 
strategies (recanalyzing, neuroprotective and neurore-
parative approaches). These latter are further subdi-
vided in models of focal and global cerebral ischemia. 
  Animal models of tissue injury in stroke are designed to 
generate reproducible infarcts in a high throughput manner 
with a minimum of surgical manipulation to determine 
mechanisms of cell death and to test novel drugs as recana-
lyzing, neuroprotective, neuroregenerative and anti- inflam-
matory therapies [1]. 
  The various methods to induce strokes in rodents reflect 
the complexity of the disease, and the need of different para-
digms to optimize the study of therapeutical approaches. 
MODELS FOR THE STUDY OF THE PATHOPHYSI-
OLOGY AND THERAPIES FOR STROKE 
  Models of cerebral ischemia can be separated into focal 
and global ischemia models. Focal ischemia is characterized 
by a reduction of cerebral blood flow in a distinct region of 
the brain, whereas in global ischemia the reduction of blood 
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bral ischemia, either an artery or vein is occluded mechani-
cally or by cerebral thromboembolism. 
Models for Inducing Focal Cerebral Ischemia 
  Stroke caused by an acute cerebral vessel occlusion can 
be reproduced by different techniques, namely by mechani-
cal occlusion of either the proximal middle cerebral artery 
(pMCAo) (large vessel occlusion) or distal MCA (dMCAo) 
(small vessel occlusion), or by thrombotic occlusion either 
via injection of blood clots or thrombin into the MCA or by 
photo-thrombosis after intravenous injection of Rose Bengal. 
Besides models for arterial stroke also animal models for 
cerebral venous sinus thrombosis, a rare form of stroke that 
results from thrombosis of the dural venous sinuses, have 
been developed. 
a. Mechanical occlusion of the MCA 
  pMCAo models belong to the most frequently used pro-
cedures in stroke research. pMCAo is usually induced by 
direct mechanical occlusion, most often through the insertion 
of a silicon-coated nylon suture into the internal carotid ar-
tery that is subsequently advanced to the circle of Willis to 
occlude the MCA at its origin. The severity of ischemic in-
jury can be modeled by leaving the suture filament in place 
either transiently for a variable duration of time (time usually 
ranges between 30-120 min) before the suture is removed to 
allow tissue reperfusion. In case of permanent pMCAo the 
suture is left in place and no reperfusion is allowed. Short-
lasting pMCAo causes selective neuronal death in the lesion-
sided striatum, expression of heat shock proteins, immediate 
early gene expression and induction of apoptotic signal path-
ways in the overlying cortex [6, 7]. Longer durations of 
occlusion instead result in brain infarcts that involve both the 
striatum and cortex [8], and may be associated with some 
animal mortality in case of edema formation. Intracranial 
hypertension due to edema is frequently observed in animals, 
in which brain injury develops in deep brain structures com-
prising the thalamus and midbrain. One disadvantage with 
this model, i.e. the intraluminal MCA occlusion, is that injur-
ing these structures is unavoidable in some. However alto-
gether pMCAo has the advantage of its high reproducibility 
and that it does not require craniotomy (avoiding possible, 
although rare complications) and that the resulting focal 
brain damages are similar to those occurring in human stroke 
[9, 10]. 
  Distal vascular occlusions, dMCAo, can be on the other 
hand performed through a craniotomy to directly expose and 
manipulate superficial MCA branches. Compared to 
pMCAo, the damage with distal occlusions is more restricted 
as the occluded vessel is superficial. Usually the MCA is 
occluded either transiently or permanently distal to the
 origin 
of the lenticulostriate branches by means of a clip or by elec-
trocoagulation [11, 12]. Deep structures of the brain as 
thalamus hypothalamus, hippocampus and midbrain are 
spared but the procedure, though seldom, may be associated 
with some complications like side effects of the craniotomy 
as subarachnoidal bleeding, cerebral infection, mechanical 
induction of spreading depression and cerebrospinal fluid 
leakage [1]. 
  dMCAo can also be combined with either ipsilateral 
permanent or bilateral transient common carotid artery oc-
clusion. Ischemic damage may involve the frontal, parietal 
and temporal cortex. With these latter technique, the under-
lying white matter together with a small area of the lateral 
striatum may be involved as well [13-15].  
  As selective damage in the cortex can be reproduced 
without the involvement of deep structures the model of 
dMCAo is particularly suited for studying neuroplasticity 
rearrangements after stroke and neuroregeneration cues. 
b. Thromboembolic Models 
  As human stroke is most frequently caused by cerebral 
thromboembolism, a number of animal models has been de-
veloped that closely mimic the embolic occlusion of brain 
vessels. Embolic strokes can be induced in animals through 
injection of large-sized synthetic macrospheres (300-400 m 
diameter) or small-sized microspheres (less than 50 m) into 
the internal carotid artery. In the first case, large infarcts 
similar to those produced by the permanent occlusion of the 
MCA are induced. In the latter case, smaller, multifocal in-
farcts can occur [16, 17].  
  To study thrombolytic therapies (a clinically very rele-
vant therapeutical issue), a third model of vascular occlusion 
has been developed using autologous blood clots that are 
injected directly into the internal carotid artery [18-22]. Em-
bolic stroke models produce relatively variable infarcts that 
make it more difficult to test neuroprotective therapies; nev-
ertheless they are well suited to study reperfusion therapies 
[23].  
  Very recently a novel mouse model of in situ throm-
boembolic stroke has been described [24]. Generation of an 
autologous thrombus directly into the MCA induced by the 
local injection of purified thrombin resulted in very repro-
ducible ischemic injury volumes. In this thromboembolic 
model recombinant tissue plasminogen activator (rtPA) de-
livery resulted in a significant reduction of brain injury. Such 
local delivery techniques might be applied in the previously 
described models to overcome the low reproducibility of 
ischemic infarcts [25]. Nonetheless the positioning of intra- 
arterial catheters for thrombus injection might produce en-
dovascular injuries and subsequent inflammatory processes. 
Whether such bystander injuries can be prevented by refine-
ments of clot delivery techniques need to be assessed. 
  Unfortunately, thromboembolic stroke models have 
achieved limited significance in neuroprotection research in 
the past, due to their variability, thus accounting for the 
translation failure of animal data to humans. In fact, me-
chanical occlusion models poorly reflected the hemodynamic 
aspects of thrombolytic reperfusion, which potentially might 
lead to an altered responsiveness of the brain tissue to neuro-
protective treatments. The latter idea is supported by obser-
vations regarding the progression of metabolic disturbances 
and energy failure after cerebral thromboembolism followed 
by thrombolysis in mice [26], which differed from intralu-
minal MCA occlusion findings [7, 8, 27]. It remains to be 
awaited whether the refinement of models might in the near 
future give the opportunity to study more precisely the effect 
of recanalizing strategies in animal models. 
c. The endothelin and the photothrombosis model 
  As the more commonly used models (suture model and 
distal middle cerebral artery occlusion) are often technically 
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sion have been developed as an alternative. One of these 
methods consists in the intracerebral injection of vasocon-
strictor substances as endothelin-1 (ET-1) that causes a le-
sion by reducing acutely the blood flow in the circumscribed 
injected area [28]. Although this has been reported as a sim-
ple and reproducible method of focal ischemia in rats [28, 
29] the intracerebral injection of ET-1 in mice often does not 
produce a lesion [30]. In mice it is therefore necessary to 
combine ET-1 injection with either common carotid artery 
(CCA) occlusion or N(G)-nitro-larginine methyl ester (l-
NAME) injection or both to produce a reproducible lesion 
resulting also in a significant motor deficit. This model has 
therefore the advantage of being technically easier and faster 
than other rat stroke models however it does not confer other 
advantages (no precise localization of the lesion to the site of 
injection, similar mortality rate as other stroke models) [30]. 
  Another technique to induce localized stroke consists of 
the photothrombosis of an injected photosensitive dye. This 
is induced by the trans-cranial illumination of the brain after 
the systemic delivery of a photosensitive dye (Rose Bengal), 
obtaining the coagulation of the irradiated tissue [31]. This 
model has the advantage that the region of ischemia can be 
predefined and highly circumscribed, opening the possibility 
to coagulate distinct cortical areas with stereotactical preci-
sion. The disadvantages of this model are the non-
physiologic insult (photocoagulation) that creates a lesion 
with a small ischemic penumbra compared to other focal 
stroke models as described above. Further, because of the 
damage of the vessels induced by the “photothrombo-
sis",substantial local vasogenic edema forms early after in-
farction [1]. 
d. Cerebral Venous Thrombosis Models 
  Cerebral veins and sinus thrombosis (CVT) is a distinct 
cerebrovascular disorder that affects young adults and chil-
dren more often than arterial stroke. The acute or chronic 
thrombosis of cerebral veins and/or sinuses is the underlying 
cause. During the past decade, increased awareness of the 
diagnosis, improved neuroimaging techniques, and more 
effective treatments have remarkably improved the prognosis 
[32]. The first report on animal models of CVT is of the year 
1836 in a rabbit by tying both jugular veins [33]. Since then 
various other animal models of CVT have been developed in 
cats, pigs, dogs, rabbits and rodents [34]. However rat mod-
els are more reliable because of their anatomy of the cerebral 
brains and sinuses. CVT can be induced by different meth-
ods: occlusion of the superior sagittal sinus can be induced 
by direct injection of various chemical substances (cya-
noacrylate, ethanolamine or other sclerosing agents) into the 
sinus. Other techniques make use of direct mechanical or 
heat damage to the superior sagittal sinus. Another rat model 
of CVT is induced by the photochemical coagulation of the 
dorsal cerebral veins after injection of Rose Bengal [35]. 
Unfortunately, the induction of CVT is often insufficient to 
mimic neuropathological consequences of CVT [2]. 
Models for Inducing Global Cerebral Ischemia 
  Global cerebral ischemia, characterized by the critical 
reduction of cerebral blood flow in the whole brain, induces 
selectively neuronal injury in the CA1 region of the hippo-
campus as long as the duration of ischemia is limited. Upon 
extension of ischemia, other brain areas get involved, and at 
a critical duration a so-called no-reflow phenomenon takes 
place in which the restoration of blood flow is unsuccessful 
[36-38].  
  Models of global cerebral ischemia are usually used to 
study brain damage that occurs in cardio-circulatory resusci-
tation.  
  Global ischemia can be induced by means of different 
approaches. The so called ‘four vessel occlusion method’ 
(4VO) consists of a reversible CCA occlusion, which, com-
bined with permanent interruption of the vertebral arteries 
via  electro cauterization, results in bilateral forebrain and 
brainstem ischemia with a highly predictable brain damage 
[39].  
  As alternative to the 4VO method, global ischemia can 
also be induced by the occlusion of the two common carotid 
arteries, i.e., by two vessel occlusion (2VO) together with 
induction of hypotension for a limited time period. In this 
forebrain ischemia model, selective injury in the CA1 of the 
hippocampus, the caudate putamen and neocortex is ob-
served [40]. 
  The mongolian Gerbils, small mammal of the order Ro-
dentia, are widely used in models of chronic or transient 
forebrain ischemia due to specie-specific incomplete circle 
of Willis, i.e. absence of communicating arteries between the 
middle and posterior cerebral arteries. For this anatomic pe-
culiarity chronic bilateral common carotid stenosis using 
steel coils produces prolonged hypoperfusion, with a 25% 
reduction in cerebral blood flow [41]. On neuropathology the 
chronic hypoperfusion reflects as small necrotic foci in the 
cortex and the basal ganglia, accompanied by intense gliosis 
and small vessel proliferation. If the common carotid arteries 
are transiently occluded (10 minutes long) neuronal death in 
the hippocampus is observed [42]. These changes are also 
accompanied by various behavioral impairments as a spatial 
learning and memory deficits that varies with the degree and 
the duration of hypoperfusion. However the gerbils might 
present various problems when used in models for global 
cerebral ischemia, as many animals have not a totally in-
complete circle of Willis, i.e. small communicating arteries 
give collateral supply to the forebrain [43]. 
  Another technique for inducing a global cerebral ische-
mia that is very close to that occurring in the human during 
cardiac arrest consists in the induction of ventricular fibrilla-
tion followed shortly thereafter by defibrillation combined 
with chest compression and administration of epinephrine. 
This technique is commonly performed in large animals spe-
cies due to its complexity and the fact that complete inten-
sive care treatment must be ensured during the first couple of 
days after resuscitation [44, 45] even though it has also been 
successfully adapted to small rodents [46]. 
  Models of global cerebral ischemia have widely been 
used in large mammals as the dog and the pig, since cardio-
circulatory variables can be controlled similar to humans in 
these animals. Mouse models were initially less common as 
they were hampered by a high mortality rate and frequent 
complication that included most often seizures [4]. Due the 
need to use transgenic or knockout mutant mice, global 
ischemia was recently induced in mice by the bilateral occlu-
sion of the common carotid artery in association with con-
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the induction of cardiac arrest (8-10 min), followed by car-
dio-pulmonary resuscitation. This latter model is in fact 
characterized by a selective injury of neurons in the hippo-
campus and striatum [48].  
  Animal models discussed have been resumed in Table 1. 
CONCLUSION: RESEARCH RECOMMENDATIONS 
AND ETHICAL ISSUES 
  Research projects should be designed on the basis of 
state-of-the-art recommendations on preclinical and clinical 
studies, e.g., made by the Stroke Therapy Academic Industry 
Roundtable (STAIR), [49-51] that aim to provide common 
standards and to increase the success of drug developments. 
These recommendations request experimental works to be 
performed over species and sex barriers, providing dose-
response relationships and time windows for drug applica-
tion before studies should enter clinical testing. The inclu-
sion of physiological measurements and functional readouts 
in addition to morphological data analysis for animal studies 
is also recommended. One major problem that is nonetheless 
present and difficult to overcome is that stroke research is 
mostly conducted in young laboratory animals and thus does 
not consider that the vast majority of strokes in humans that 
occur in elderly subjects affected by a multiplicity of other 
co-morbidities and risk factors, such as arterial hypertension, 
diabetes and atherosclerosis. The authors recognize an in-
creasing need to include more and more experiments evalu-
ating ischemic injury evolution in animal lines at risk for 
vascular injury, such as in atherosclerotic, diabetic mice or 
aged rats.  
  It must critically be mentioned though that until the pre-
sent stage, not many experimental stroke studies made use of 
the pool of transgenic animals at vascular risk described in 
the first part of this review. Clearly, research is needed in 
that area, analyzing how the responsiveness of the brain is 
altered in animals in which the vascular system is compro-
mised. Although no single animal precisely reproduces hu-
man ischemic stroke (the underlying risk factors and condi-
tions are heterogeneous and complex), the lack of studies in 
that field from our view might represent an important reason 
for study failures in clinics. With such strategies, the authors 
would not be surprised if neuroprotection, which has been a 
problem for a considerable duration of time, would become 
feasible also in human patients. 
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